Second-line treatment of HER2-positive metastatic breast cancer: Trastuzumab beyond progression or lapatinib? A population based cohort study

  • Ariel Hammerman
  • , Sari Greenberg-Dotan
  • , Ilan Feldhamer
  • , Haim Bitterman
  • , Rinat Yerushalmi

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Second-line treatment of HER2-positive metastatic breast cancer: Trastuzumab beyond progression or lapatinib? A population based cohort study'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science